Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
CapVest Closes Deal to Acquire Controlling Stake in STADA
International investment firm CapVest Partners has officially announced the...
Eli Lilly to Acquire Centessa Pharmaceuticals for $7.8 Billion to Advance Sleep Disorders Portfolio
Pharmaceutical corporation Eli Lilly has announced a definitive agreement...
EMA Publishes GMDP Inspectors Work Plan for 2026–2028: Focus on AI, Supply Chain Protection, and Global Partnership
The European Medicines Agency (EMA) has presented the three-year...
Top 10 Big Pharma Companies by R&D Spending in 2025 Published
The past year, 2025, proved to be a period...
American Scientists Create an Implant That Autonomously Produces Drugs Inside the Body
An inter-institutional team of researchers led by Northwestern University,...
Russia Approves First National Standard for 3D Bioprinting of Tissues and Organs
Russia has officially adopted the first national standard regulating...
Published Amendments to the EAEU Veterinary Drugs Circulation Rules: The Transition Period has been Extended until 2030
On March 25, the text of EEC Council Decision...
Rosselkhoznadzor has received authority to issue veterinary EAEU GMP certificates
In Russia, the legal framework for issuing EAEU GMP...
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
AI and Billion-Dollar Investments: Eli Lilly Signs an Agreement with Insilico Medicine Worth Up to $2.75 Billion
American pharmaceutical giant Eli Lilly continues to actively invest in artificial intelligence technologies and biotechnological developments.
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
CapVest Closes Deal to Acquire Controlling Stake in STADA
International investment firm CapVest Partners has officially announced the...
Eli Lilly to Acquire Centessa Pharmaceuticals for $7.8 Billion to Advance Sleep Disorders Portfolio
Pharmaceutical corporation Eli Lilly has announced a definitive agreement...
EMA Publishes GMDP Inspectors Work Plan for 2026–2028: Focus on AI, Supply Chain Protection, and Global Partnership
The European Medicines Agency (EMA) has presented the three-year...
Top 10 Big Pharma Companies by R&D Spending in 2025 Published
The past year, 2025, proved to be a period...
American Scientists Create an Implant That Autonomously Produces Drugs Inside the Body
An inter-institutional team of researchers led by Northwestern University,...
Russia Approves First National Standard for 3D Bioprinting of Tissues and Organs
Russia has officially adopted the first national standard regulating...
Published Amendments to the EAEU Veterinary Drugs Circulation Rules: The Transition Period has been Extended until 2030
On March 25, the text of EEC Council Decision...
Rosselkhoznadzor has received authority to issue veterinary EAEU GMP certificates
In Russia, the legal framework for issuing EAEU GMP...
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
AI and Billion-Dollar Investments: Eli Lilly Signs an Agreement with Insilico Medicine Worth Up to $2.75 Billion
American pharmaceutical giant Eli Lilly continues to actively invest in artificial intelligence technologies and biotechnological developments.
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
GMP Registry Update: 16 New Certificates at the Turn of March and April 2026
The Ministry of Industry and Trade of the Russian...
VGNKI Inspects Four Foreign Veterinary Drug Manufacturers Since Early 2026
Between January and April 3, 2026, the Russian State...
Faberlic to Invest Nearly 1 Billion Rubles in Dietary Supplement Production in Moscow Region
Faberlic Natural Labs (part of JSC Faberlic) has received...
CapVest Closes Deal to Acquire Controlling Stake in STADA
International investment firm CapVest Partners has officially announced the...
